Product Information
TRI-ESTARYLLA TABLET is a generic product labeled by Xiromed LLC, priced at $0.1264 per EA under NDC 70700012185. Its NADAC has been published 384 times since May 29, 2019.
FDA first approved this application on Jan 30, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Xiromed LLCNDC
70700012185
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA090793FDA Approved
1/30/2013
TE Code
AB
On Market Since
9/1/2022
Price Statistics
The NADAC for TRI-ESTARYLLA TABLET has been published 384 times since May 29, 2019, and over the history we have for it it has declined 42.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1264 per EA |
|---|---|
| All-time high | $0.2207 (Jun 10, 2020) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1375 |
| 52-week low | $0.1259 |
| Median price | $0.1432 |
| Average price | $0.1567 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 384 |
| Tracking since | May 29, 2019 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norgestimate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI-ESTARYLLA TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-ESTARYLLA TABLET, manufactured by Xiromed LLC, is $0.1264 per EA (NDC 70700012185), effective Sep 30, 2026.
How has the price of TRI-ESTARYLLA TABLET changed over time?
Over the history we have for it, the NADAC for TRI-ESTARYLLA TABLET has declined 42.1%. It has been tracked across 384 weekly CMS publications since May 29, 2019.
What are the highest and lowest recorded NADAC prices for TRI-ESTARYLLA TABLET?
Since May 29, 2019, the NADAC for TRI-ESTARYLLA TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2207 (Jun 10, 2020), with a median of $0.1432 per EA.
Are there cheaper alternatives to TRI-ESTARYLLA TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-LO-ESTARYLLA TABLET, is $0.1080 per EA — about 15% below TRI-ESTARYLLA TABLET.
Who manufactures TRI-ESTARYLLA TABLET?
TRI-ESTARYLLA TABLET (NDC 70700012185) is labeled by Xiromed LLC, and CMS classifies it as a generic product.